Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay

Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet